Gastrointestinal CancersNCT04724070
PRecision Oncology CUhk pRogrammE (PRO-CURE)
An observational study of Gastrointestinal Cancers, run by Brigette Ma at 1 site in Hong Kong.
Trial summary
The main aim of this project is to establish an innovative model of a comprehensive precision oncology platform to help individualizing drug therapy for patients with advanced cancers at The Chinese University of Hong Kong. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Gastrointestinal Cancers
- What is being tested?
- NGS, PDO/PDX establishment
- How many people
- 170 participants
- Where
- 1 siteHong Kong
- Study dates
- 16 Oct 2019to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The cancer types that are allowed in this study: * Gastrointestinal cancers: esophageal cancer, colorectal cancer, gastric cancer, esophago-gastric junction cancer, pancreatic cancer (including neuroendocrine cancers), small bowel cancer, appendiceal cancer, anal cancer. * Cancers that are known to carry unique genomic aberrations that are clinically relevant and/or potentially actionable. Excluded types of neoplastic or dysplastic disorders: - Lymphoma, leukemia, lymphoproliferative disease, plasma cell neoplasms, histiocytosis-related proliferative disorders.
Who may be able to join
- Must be aged between 18 to 75 years
- Must have ECOG performance status of 0 to 1
- Must have histologically/cytologically confirmed cancers of certain subtype
- Medically fit patients who would need systemic therapy as part of their oncological treatment in any one or more of the following oncological setting(s): palliative, neoadjuvant, adjuvant, concurrent with radiotherapy. This includes patients who have limited systemic therapeutic options for their cancers and are candidates for clinical trials.
- Able to give written informed consent
- Willing to have blood samples taken.
- Availability of an archived paraffin-embedded tumor block
Who cannot join
- Patients who refuse or are medically unfit for systemic therapy for their cancer
- Patients with more than one invasive cancers diagnosed over the last FIVE years.
- Patients without measurable tumor lesions on radiological imaging
- Patients who are unable to give written informed consent.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comprehensive Precision Oncology Program at The Chinese University of Hong Kong
The main aim of this project is to establish an innovative model of a comprehensive precision oncology platform to help individualizing drug therapy for patients with advanced cancers at The Chinese University of Hong Kong. The other objectives include to optimize the genomic matching and access of patients with unique cancer subtypes to the relevant clinical trials of novel therapies, and to construct a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues. Other objectives include to investigate the utility and feasibility of genomic sequencing using circulating tumor DNA(ctDNA), and to establish a biobank of tumor tissues derived from patients with unique cancer subtypes.
- Conditions
- Gastrointestinal Cancers
- Being tested
- NGS, PDO/PDX establishment
- Medical subject headings
- Gastrointestinal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NGS, PDO/PDX establishmentGenetic
Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.
| Study group | Role | What they receive |
|---|---|---|
| NGS and PDO/PDX establishment | Not described Receives: Genetic: NGS, PDO/PDX establishment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Establishment of an innovative model of a comprehensive precision oncology platform
Measured: 4 years
Construction of a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues.
Measured: 4 years
Secondary outcomes (1)
Describe the prevalence of actionable genomic aberrations in patients with advanced cancers in Hong Kong
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2021
- Study start16 Oct 2019
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastrointestinal CancersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 170 participants (actual)
Sponsor and investigators
- Lead sponsor
- Brigette Ma
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Brigette Ma, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04724070
- Sponsor's protocol ID
- PROCURE
- Status last verified
- Jun 2026
- First submitted
- 21 Jan 2021
- Last updated
- 18 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comprehensive Precision Oncology Program at The Chinese University of Hong Kong
- ClinicalTrials.gov ID
- NCT04724070
- Acronym / sponsor ID
- PROCURE
- Conditions
- Gastrointestinal Cancers
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 170 participants (actual)
- Lead sponsor
- Brigette MaUniversity, hospital or other
- Study start
- 16 Oct 2019 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 26 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main aim of this project is to establish an innovative model of a comprehensive precision oncology platform to help individualizing drug therapy for patients with advanced cancers at The Chinese University of Hong Kong. The other objectives include to optimize the genomic matching and access of patients with unique cancer subtypes to the relevant clinical trials of novel therapies, and to construct a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues. Other objectives include to investigate the utility and feasibility of genomic sequencing using circulating tumor DNA(ctDNA), and to establish a biobank of tumor tissues derived from patients with unique cancer subtypes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| NGS and PDO/PDX establishment | – | Genetic: NGS, PDO/PDX establishment |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The cancer types that are allowed in this study: * Gastrointestinal cancers: esophageal cancer, colorectal cancer, gastric cancer, esophago-gastric junction cancer, pancreatic cancer (including neuroendocrine cancers), small bowel cancer, appendiceal cancer, anal cancer. * Cancers that are known to carry unique genomic aberrations that are clinically relevant and/or potentially actionable. Excluded types of neoplastic or dysplastic disorders: - Lymphoma, leukemia, lymphoproliferative disease, plasma cell neoplasms, histiocytosis-related proliferative disorders.
Key inclusion criteria (7 listed)
- Must be aged between 18 to 75 years
- Must have ECOG performance status of 0 to 1
- Must have histologically/cytologically confirmed cancers of certain subtype
- Medically fit patients who would need systemic therapy as part of their oncological treatment in any one or more of the following oncological setting(s): palliative, neoadjuvant, adjuvant, concurrent with radiotherapy. This includes patients who have limited systemic therapeutic options for their cancers and are candidates for clinical trials.
- Able to give written informed consent
Key exclusion criteria (4 listed)
- Patients who refuse or are medically unfit for systemic therapy for their cancer
- Patients with more than one invasive cancers diagnosed over the last FIVE years.
- Patients without measurable tumor lesions on radiological imaging
- Patients who are unable to give written informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NGS, PDO/PDX establishmentPatients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking. | Genetic | NGS and PDO/PDX establishment |
Primary outcome
Establishment of an innovative model of a comprehensive precision oncology platform
Time frame: 4 years
Construction of a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues.
Time frame: 4 years
1 secondary outcome
Describe the prevalence of actionable genomic aberrations in patients with advanced cancers in Hong Kong
Time frame: 4 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Gastrointestinal Cancers
RecruitingPhase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Endocrine Tumors, Non-Small Cell Lung Cancer
Recruiting
Perioperative Multicomponent Rehabilitation and Outcomes in Elderly Patients With Frailty
Old Age; Debility, Digestive Cancer
Active, not recruiting
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
Breast Cancer, Lung Cancer
RecruitingObservational study
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Non-GI Cancers, Cancer of Gastrointestinal Tract
RecruitingObservational study
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Gastric Cancer, Gastric Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastrointestinal Cancers, run by Brigette Ma at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Establishment of an innovative model of a comprehensive precision oncology platform (time frame: 4 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026; AzTrials last refreshed its copy on 2 Nov 2026.